Equities
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy4
Outperform3
Hold17
Sell2
Strong Sell0

Share price forecast in USD

The 21 analysts offering 12 month price targets for Novartis AG have a median target of 104.29, with a high estimate of 118.20 and a low estimate of 84.43. The median estimate represents a 6.38% increase from the last price of 98.04.
High20.6%118.20
Med6.4%104.29
Low-13.9%84.43

Dividends in USD

In 2023, Novartis AG reported a dividend of 3.92 USD, which represents a 13.28% increase over last year. The 21 analysts covering the company expect dividends of 3.84 USD for the upcoming fiscal year, a decrease of 2.03%.
Div growth (TTM)13.28%
More ▼

Earnings history & estimates in USD

On Jul 18, 2024, Novartis AG reported 2nd quarter 2024 earnings of 1.97 per share. This result exceeded the 1.87 consensus of the 10 analysts covering the company and exceeded last year's 2nd quarter results by 7.65%.
The next earnings announcement is expected on Oct 29, 2024.
Average growth rate+2.67%
Novartis AG reported annual 2023 earnings of 6.90 per share on Jan 31, 2024.
Average growth rate+6.48%
More ▼

Revenue history & estimates in USD

Novartis AG had 2nd quarter 2024 revenues of 12.51bn. This bettered the 12.36bn consensus of the 10 analysts covering the company. This was 3.40% below the prior year's 2nd quarter results.
Average growth rate-1.81%
Novartis AG had revenues for the full year 2023 of 45.44bn. This was 10.10% below the prior year's results.
Average growth rate-0.88%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.